Biotech Startup Pahr Therapeutics Raises $14M to Advance Clinical Programs for PAH

Pahr Therapeutics, a clinical-stage biotech company with operations in Boston, MA, and Osaka, Japan, has secured $14 million in seed funding to advance its therapies for pulmonary arterial hypertension (PAH), a rare and severe lung disease. The round was led by RA Capital Management, AN Venture Partners, and University of Tokyo Edge Capital Partners (UTEC).

The company plans to use the fresh capital to accelerate the development of its novel PAH treatments and expand its research efforts. 

Pahr Therapeutics plans to deploy the seed funding toward advancing its therapies for pulmonary arterial hypertension (PAH), focusing on developing novel mechanisms to address the disease. The company aims to move its programs toward clinical studies, targeting early trials next year.

Pahr Therapeutics was nurtured at Raven, the startup incubator of RA Capital Management, and is headed by Neil Buckley, a Venture Partner at Raven. The company was co-founded by Drs. Ryotaro Asano, Makoto Okazawa, and Yoshikazu Nakaoka from  Cardiovascular Center (NCVC) and the National Cerebral, Japan.

Dr. Nakaoka, head of the Vascular Physiology Department at NCVC, has dedicated years to exploring the molecular mechanisms behind PAH. His work has been instrumental in shaping Pahr Therapeutics’ strategy for developing next-generation treatments for the disease.

As part of the investment, Atsushi Usami of UTEC, Ken Horne of AN Venture Partners, and Andrew Levin from RA Capital Management have joined Pahr Therapeutics’ board of directors. Their collective background in biotech investment and company-building is expected to guide the startup in advancing its clinical pipeline and supporting future growth.

Commenting on the milestone, Dr. Nakaoka expressed optimism about bringing new therapies to PAH patients and highlighted the importance of global investor support. He said the collaboration with the investors and his mentorship experience with Andrew Levin were instrumental in shaping Pahr’s formation and direction.

Pahr Therapeutics’ work has seen the growing interest in startups addressing rare and serious conditions like PAH, where treatment options remain limited. By combining Japanese research expertise with U.S. venture backing, the company aims to deliver therapies that could transform care for patients with this life-threatening disease.